Tags

Type your tag names separated by a space and hit enter

Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
Eur Urol. 2005 May; 47(5):695-702.EU

Abstract

BACKGROUND

Evidence suggests that the insulin-like growth factor (IGF) family is important in prostate cancer. We evaluate the ability of IGF markers to predict biochemical recurrence-free survival (bRFS) following radical prostatectomy (RRP).

METHODS

Preoperative sera from 141 patients undergoing RRP were analyzed for IGF-I, IGFBP-1, IGFBP-2 and IGFBP-3. A multivariate Cox model was created to assess the ability of these markers to predict bRFS. Preoperative covariables included: biopsy Gleason score, clinical TNM stage, serum PSA and neoadjuvant hormonotherapy. Kaplan-Meier curves were stratifying by IGF cutpoints (determined by ROC analysis) and hormonotherapy status.

RESULTS

Average follow-up was 6.92 years, median PSA was 6.9 ng/ml and 85.1% of patients had cT2NxM0 disease. 49 patients experienced a PSA failure. Average levels of IGF-I, IGFBP-1, IGFBP-2 and IGFBP-3 were 156.5 ng/ml, 48.1 ng/ml, 396.8 ng/ml and 3303.7 ng/ml, respectively. IGFBP-2 was an independent predictor of PSA failure. Patients treated with neoadjuvant ADT (n=71) and whom had high IGFBP-2 levels experienced a 5-year bRFS that was better than those with low IGFBP-2 levels (77.7% vs. 53.3%). Patients without neoadjuvant ADT whom had high IGFBP-2 levels had a 5-year bRFS that was worse than those with low IGFBP-2 levels (64.5% vs. 82.7%).

CONCLUSIONS

Preoperative IGFBP-2 predicts post-radical prostatectomy bRFS and is independent of stage, Gleason score and PSA. Increased IGFBP-2 is associated with better survival in patients with neoadjuvant hormonotherapy but worse survival in those without, suggesting a dramatic switch in function of this protein dependent on the presence or absence of androgens.

Authors+Show Affiliations

Division of Urology, Laval University, CRHDQ, 11 côte du Palais, Québec, QC, Canada G1R 2J6. brantinman@videotron.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

15826765

Citation

Inman, Brant A., et al. "Insulin-like Growth Factor Binding Protein 2: an Androgen-dependent Predictor of Prostate Cancer Survival." European Urology, vol. 47, no. 5, 2005, pp. 695-702.
Inman BA, Harel F, Audet JF, et al. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol. 2005;47(5):695-702.
Inman, B. A., Harel, F., Audet, J. F., Meyer, F., Douville, P., Fradet, Y., & Lacombe, L. (2005). Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. European Urology, 47(5), 695-702.
Inman BA, et al. Insulin-like Growth Factor Binding Protein 2: an Androgen-dependent Predictor of Prostate Cancer Survival. Eur Urol. 2005;47(5):695-702. PubMed PMID: 15826765.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. AU - Inman,Brant A, AU - Harel,François, AU - Audet,Jean-François, AU - Meyer,François, AU - Douville,Pierre, AU - Fradet,Yves, AU - Lacombe,Louis, Y1 - 2005/01/24/ PY - 2004/10/31/received PY - 2004/12/20/accepted PY - 2005/4/14/pubmed PY - 2005/8/17/medline PY - 2005/4/14/entrez SP - 695 EP - 702 JF - European urology JO - Eur. Urol. VL - 47 IS - 5 N2 - BACKGROUND: Evidence suggests that the insulin-like growth factor (IGF) family is important in prostate cancer. We evaluate the ability of IGF markers to predict biochemical recurrence-free survival (bRFS) following radical prostatectomy (RRP). METHODS: Preoperative sera from 141 patients undergoing RRP were analyzed for IGF-I, IGFBP-1, IGFBP-2 and IGFBP-3. A multivariate Cox model was created to assess the ability of these markers to predict bRFS. Preoperative covariables included: biopsy Gleason score, clinical TNM stage, serum PSA and neoadjuvant hormonotherapy. Kaplan-Meier curves were stratifying by IGF cutpoints (determined by ROC analysis) and hormonotherapy status. RESULTS: Average follow-up was 6.92 years, median PSA was 6.9 ng/ml and 85.1% of patients had cT2NxM0 disease. 49 patients experienced a PSA failure. Average levels of IGF-I, IGFBP-1, IGFBP-2 and IGFBP-3 were 156.5 ng/ml, 48.1 ng/ml, 396.8 ng/ml and 3303.7 ng/ml, respectively. IGFBP-2 was an independent predictor of PSA failure. Patients treated with neoadjuvant ADT (n=71) and whom had high IGFBP-2 levels experienced a 5-year bRFS that was better than those with low IGFBP-2 levels (77.7% vs. 53.3%). Patients without neoadjuvant ADT whom had high IGFBP-2 levels had a 5-year bRFS that was worse than those with low IGFBP-2 levels (64.5% vs. 82.7%). CONCLUSIONS: Preoperative IGFBP-2 predicts post-radical prostatectomy bRFS and is independent of stage, Gleason score and PSA. Increased IGFBP-2 is associated with better survival in patients with neoadjuvant hormonotherapy but worse survival in those without, suggesting a dramatic switch in function of this protein dependent on the presence or absence of androgens. SN - 0302-2838 UR - https://www.unboundmedicine.com/medline/citation/15826765/Insulin_like_growth_factor_binding_protein_2:_an_androgen_dependent_predictor_of_prostate_cancer_survival_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0302-2838(04)00641-4 DB - PRIME DP - Unbound Medicine ER -